BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...proteins Metastatic castration-resistant prostate cancer (CRPC) Phase I $40.9 Eastern Capital; NGN BioMed Opportunity II Argonaut Therapeutics Ltd....
...Phase I testing. Constellation's EZH2 inhibitor CPI-1205 is in Phase I testing for lymphomas, and Argonaut Therapeutics Ltd....
...super-enhancers, and to map super-enhancers to identify new cancer driver targets. Companies and Institutions Mentioned Argonaut Therapeutics Ltd....
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...Ltd. £15.5M ($21.8M) Ophthalmic delivery platform Ophthalmic; Drug delivery Preclinical Oxford Sciences Innovation plc (2015) Argonaut Therapeutics Ltd....
...new antigen receptors (VNARs) University of Aberdeen Ophthalmic; cancer Deepbridge Capital ; Scottish Investment Bank Argonaut Therapeutics Ltd....
BioCentury | Feb 14, 2017
Emerging Company Profile

Divide or conquer

...Argonaut plans to raise an undisclosed amount of venture funding within a year. COMPANY PROFILE Argonaut Therapeutics Ltd....
...2 issued covering biomarkers to identify tumors responsive to PRMT5 inhibition Companies and Institutions Mentioned Argonaut Therapeutics Ltd....
...of Oxford, Oxford, U.K. References Parmley, S. “Epizyme’s mantle piece.” BioCentury Innovations (2015) Emily Cukier-Meisner, Senior Writer Argonaut Therapeutics Ltd. Protein...
BioCentury | Oct 24, 2016
Financial News

Argonaut Therapeutics completes venture financing

Argonaut Therapeutics Ltd. , Oxford, U.K. Business: Cancer Date completed: 2016-10-19 Type: Venture financing Raised: Not disclosed Investor: Oxford Sciences Innovation plc Note: The amount raised is not disclosed....
Items per page:
1 - 4 of 4
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...proteins Metastatic castration-resistant prostate cancer (CRPC) Phase I $40.9 Eastern Capital; NGN BioMed Opportunity II Argonaut Therapeutics Ltd....
...Phase I testing. Constellation's EZH2 inhibitor CPI-1205 is in Phase I testing for lymphomas, and Argonaut Therapeutics Ltd....
...super-enhancers, and to map super-enhancers to identify new cancer driver targets. Companies and Institutions Mentioned Argonaut Therapeutics Ltd....
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...Ltd. £15.5M ($21.8M) Ophthalmic delivery platform Ophthalmic; Drug delivery Preclinical Oxford Sciences Innovation plc (2015) Argonaut Therapeutics Ltd....
...new antigen receptors (VNARs) University of Aberdeen Ophthalmic; cancer Deepbridge Capital ; Scottish Investment Bank Argonaut Therapeutics Ltd....
BioCentury | Feb 14, 2017
Emerging Company Profile

Divide or conquer

...Argonaut plans to raise an undisclosed amount of venture funding within a year. COMPANY PROFILE Argonaut Therapeutics Ltd....
...2 issued covering biomarkers to identify tumors responsive to PRMT5 inhibition Companies and Institutions Mentioned Argonaut Therapeutics Ltd....
...of Oxford, Oxford, U.K. References Parmley, S. “Epizyme’s mantle piece.” BioCentury Innovations (2015) Emily Cukier-Meisner, Senior Writer Argonaut Therapeutics Ltd. Protein...
BioCentury | Oct 24, 2016
Financial News

Argonaut Therapeutics completes venture financing

Argonaut Therapeutics Ltd. , Oxford, U.K. Business: Cancer Date completed: 2016-10-19 Type: Venture financing Raised: Not disclosed Investor: Oxford Sciences Innovation plc Note: The amount raised is not disclosed....
Items per page:
1 - 4 of 4